On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally ...
Skye Bioscience Inc (SKYE) reports encouraging phase 2A study outcomes but faces increased R&D expenses and net loss.
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") today reported financial and operational results for the third quarter of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback